World's Best Scientists 2026 revealed!

D-Index & Metrics

Discipline name D-Index World Ranking Current World Ranking National Ranking Current National Ranking Publications Citations
Immunology 77 1818 1662 894 805 407 21999

Robert P. Lisak publications per year

The chart shows the history of publications by Robert P. Lisak between 1967 and 2025, highlighting the no. of papers published in each year and offering an overview of the publication velocity of this scholar. Robert P. Lisak published across 59 years, from 1967 to 2025, averaging 7.4 papers a year. Output peaked at 17 publications in 2001. 8 of the 439 publications appeared in the last two years.

No. of publications
5 10 15
Bar chart. Horizontal axis: year, 1967 to 2025. Vertical axis: number of publications, 0 to 17. Peak 17 publications in 2001. 1967: 1 publication 1968: 4 publications 1969: 1 publication 1970: 6 publications 1971: 0 publications 1972: 1 publication 1973: 2 publications 1974: 6 publications 1975: 10 publications 1976: 8 publications 1977: 8 publications 1978: 12 publications 1979: 10 publications 1980: 12 publications 1981: 15 publications 1982: 11 publications 1983: 15 publications 1984: 16 publications 1985: 6 publications 1986: 16 publications 1987: 12 publications 1988: 11 publications 1989: 5 publications 1990: 4 publications 1991: 4 publications 1992: 6 publications 1993: 6 publications 1994: 4 publications 1995: 5 publications 1996: 3 publications 1997: 6 publications 1998: 8 publications 1999: 4 publications 2000: 4 publications 2001: 17 publications 2002: 16 publications 2003: 8 publications 2004: 0 publications 2005: 3 publications 2006: 8 publications 2007: 10 publications 2008: 4 publications 2009: 8 publications 2010: 11 publications 2011: 7 publications 2012: 8 publications 2013: 11 publications 2014: 8 publications 2015: 5 publications 2016: 12 publications 2017: 4 publications 2018: 7 publications 2019: 10 publications 2020: 12 publications 2021: 10 publications 2022: 8 publications 2023: 2 publications 2024: 6 publications 2025: 2 publications
1967 2025

439 publications in total across all disciplines

View publications per year as a table
Robert P. Lisak: publications per year, 1967 to 2025
Year Publications
1967 1
1968 4
1969 1
1970 6
1971 0
1972 1
1973 2
1974 6
1975 10
1976 8
1977 8
1978 12
1979 10
1980 12
1981 15
1982 11
1983 15
1984 16
1985 6
1986 16
1987 12
1988 11
1989 5
1990 4
1991 4
1992 6
1993 6
1994 4
1995 5
1996 3
1997 6
1998 8
1999 4
2000 4
2001 17
2002 16
2003 8
2004 0
2005 3
2006 8
2007 10
2008 4
2009 8
2010 11
2011 7
2012 8
2013 11
2014 8
2015 5
2016 12
2017 4
2018 7
2019 10
2020 12
2021 10
2022 8
2023 2
2024 6
2025 2
Total 439
Download as CSV

Robert P. Lisak publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Robert P. Lisak sits on this spectrum.

No. of scientists
50 100 150
Bar chart with 76 bars. Horizontal axis: publications, 62–71 to 807+. Vertical axis: number of scientists, 0 to 189. Most scientists, 189, have 152–161 publications. The last bar groups every scientist with 807 publications or more. The highlighted bar, 402–411 publications, is where this scientist sits. 62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 69 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientist 807+ publications: 100 scientists
62–71 publications 807+

This scientist: 407 publications — 82nd percentile

82% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

View publications distribution as a table
Number of Immunology scientists by publication count, Research.com 2026 ranking edition. Based on 4,929 ranked scientists.
Publications Scientists This scientist
62–71 9
72–81 23
82–91 40
92–101 72
102–111 86
112–121 108
122–131 150
132–141 160
142–151 159
152–161 189
162–171 166
172–181 181
182–191 188
192–201 187
202–211 178
212–221 158
222–231 168
232–241 159
242–251 160
252–261 148
262–271 116
272–281 125
282–291 115
292–301 111
302–311 95
312–321 97
322–331 97
332–341 99
342–351 96
352–361 69
362–371 76
372–381 71
382–391 71
392–401 62
402–411 54 407
412–421 41
422–431 63
432–441 53
442–451 31
452–461 42
462–471 40
472–481 29
482–491 34
492–501 30
502–511 23
512–521 41
522–531 29
532–541 28
542–551 16
552–561 18
562–571 18
572–581 17
582–591 17
592–601 17
602–611 19
612–621 13
622–631 12
632–641 11
642–651 16
652–661 9
662–671 5
672–681 13
682–691 12
692–701 6
702–711 6
712–721 9
722–731 9
732–741 6
742–751 11
752–761 10
762–771 7
772–781 12
782–791 7
792–801 5
802–806 1
807+ 100
Download as CSV

Robert P. Lisak D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Robert P. Lisak sits on this spectrum.

No. of scientists
50 100 150 200
Bar chart with 60 bars. Horizontal axis: D-Index, 40–41 to 157+. Vertical axis: number of scientists, 0 to 201. Most scientists, 201, have 58–59 D-Index. The last bar groups every scientist with 157 D-Index or more. The highlighted bar, 76–77 D-Index, is where this scientist sits. 40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 163 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40–41 D-Index 157+

This scientist: 77 D-Index — 64th percentile

64% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

View D-Index distribution as a table
Number of Immunology scientists by D-index, Research.com 2026 ranking edition. Based on 4,929 ranked scientists.
D-Index Scientists This scientist
40–41 28
42–43 91
44–45 157
46–47 192
48–49 175
50–51 188
52–53 177
54–55 155
56–57 194
58–59 201
60–61 197
62–63 201
64–65 173
66–67 167
68–69 172
70–71 199
72–73 184
74–75 133
76–77 163 77
78–79 127
80–81 121
82–83 125
84–85 121
86–87 102
88–89 96
90–91 75
92–93 72
94–95 74
96–97 66
98–99 68
100–101 49
102–103 60
104–105 54
106–107 36
108–109 23
110–111 52
112–113 41
114–115 34
116–117 25
118–119 28
120–121 11
122–123 20
124–125 27
126–127 19
128–129 20
130–131 16
132–133 17
134–135 14
136–137 15
138–139 9
140–141 11
142–143 9
144–145 9
146–147 7
148–149 7
150–151 7
152–153 5
154–155 8
156 6
157+ 96
Download as CSV

Overview

Robert P. Lisak is affiliated with Wayne State University in the United States. Their research spans multiple fields, with a primary focus on medicine and biochemistry, genetics, and molecular biology. Within these domains, their work addresses molecular biology, psychiatry and mental health, cardiology and cardiovascular medicine, genetics, and neurology.

The scientist's research topics include muscle physiology and disorders, sexual function and dysfunction studies, ion channel regulation and function, cardiomyopathy and myosin studies, genetic neurodegenerative diseases, neurogenetic and muscular disorders research, and children's physical and motor development.

Robert P. Lisak has authored publications in a variety of academic venues. Frequent publication platforms include:

  • The Journal of Sexual Medicine
  • Neurology
  • Neuromuscular Disorders
  • Annals of Neurology
  • Muscle & Nerve

Recent significant papers by Robert P. Lisak and colleagues include:

  • Effect of Different Corticosteroid Dosing Regimens on Clinical Outcomes in Boys With Duchenne Muscular Dystrophy, 2022, JAMA
  • Guidelines on clinical presentation and management of nondystrophic myotonias, 2020, Muscle & Nerve
  • Population-Wide Duchenne Muscular Dystrophy Carrier Detection by CK and Molecular Testing, 2020, BioMed Research International
  • N-of-1 Trials in Neurology, 2021, Neurology
  • Seven Strategies to Integrate Equity within Translational Research in Neurology, 2024, Annals of Neurology

Collaboration is an integral part of their work. Frequent coauthors include:

  • Edward Karpman
  • Michela Guglieri
  • Michael McDermott
  • William B. Martens
  • Jeffrey Statland

Best Publications

  • Copolymer 1 reduces relapse rate and improves disability in relapsing‐remitting multiple sclerosis Results of a phase III multicenter, double‐blind, placebo‐controlled trial

    K. P. Johnson;B. R. Brooks;J. A. Cohen;C. C. Ford

  • Galactocerebroside is a specific cell-surface antigenic marker for oligodendrocytes in culture

    Martin C. Raff;Rhona Mirsky;K. L. Fields;Robert P. Lisak

  • Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study

    James F Howard;Kimiaki Utsugisawa;Michael Benatar;Hiroyuki Murai

  • Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability

    Kenneth P. Johnson;B. R. Brooks;Jeffrey A Cohen;C. C. Ford

  • Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology

    Alexander Rae-Grant;Gregory S. Day;Ruth Ann Marrie;Alejandro Rabinstein

  • Glatiramer acetate in primary progressive multiple sclerosis: Results of a multinational, multicenter, double-blind, placebo-controlled trial

    Jerry S. Wolinsky;Ponnada A. Narayana;Paul O'Connor;Patricia K. Coyle

  • Autoantibodies to Lipoprotein-Related Protein 4 in Patients With Double-Seronegative Myasthenia Gravis

    Bin Zhang;John S. Tzartos;Maria Belimezi;Samia Ragheb

  • Plasmapheresis and Guillain-Barré syndrome: analysis of prognostic factors and the effect of plasmapheresis.

    G. M. McKhann;J. W. Griffin;David Cornblath;E. D. Mellits

  • Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial.

    James F Howard;Vera Bril;Tuan Vu;Chafic Karam

  • Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years

    K. P. Johnson;B. R. Brooks;C. C. Ford;A. Goodman

  • Isolation of myelin basic protein-reactive T-cell lines from normal human blood

    James Burns;Anthony Rosenzweig;Burton Zweiman;Robert P. Lisak

  • Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Copolymer 1 Multiple Sclerosis Study Group.

    K P Johnson;B R Brooks;C C Ford;A Goodman

  • Experimental allergic neuritis induced by sensitization with galactocerebroside.

    Takahiko Saida;Kyoko Saida;Susan H. Dorfman;Donald H. Silberberg

  • Continuous long-term immunomodulatory therapy in relapsing multiple sclerosis: results from the 15-year analysis of the US prospective open-label study of glatiramer acetate:

    C. Ford;AD Goodman;K. Johnson;N. Kachuck

  • Guillain-Barré syndrome and Hodgkin's disease: three cases with immunological studies.

    Robert P. Lisak;Madeline Mitchell;Burton Zweiman;Edward Orrechio

  • Autoantibodies to agrin in myasthenia gravis patients

    Bin Zhang;Chengyong Shen;Beverly Bealmear;Samia Ragheb

  • Secretory products of multiple sclerosis B cells are cytotoxic to oligodendroglia in vitro

    Robert P. Lisak;Joyce A. Benjamins;Liljana Nedelkoska;Jennifer L. Barger

  • In vitro cell-mediated immunity of cerebrospinal-fluid lymphocytes to myelin basic protein in primary demyelinating diseases.

    Lisak Rp;Zweiman B

  • The thymus in myasthenia gravis. Evidence for altered cell populations.

    Nabih I. Abdou;Robert P. Lisak;Burton Zweiman;Ises Abrahamsohn

  • CELL TYPE-SPECIFIC MARKERS FOR HUMAN GLIAL AND NEURONAL CELLS IN CULTURE

    P. G E Kennedy;R. P. Lisak;M. C. Raff

  • Chronic cerebrospinal venous insufficiency and multiple sclerosis.

    Omar Khan;Massimo Filippi;Mark S. Freedman;Frederik Barkhof

  • In vivo demyelinating activity of sera from patients with Guillain-Barré syndrome.

    Takahiko Saida;Kyoko Saida;Robert P. Lisak;Mark J. Brown

  • Immunoreactive myelin basic protein in the cerebrospinal fluid in neurological disorders

    John N. Whitaker;Robert P. Lisak;Rifaat M. Bashir;Olive H. Fitch

  • Antibodies to Oligodendroglia in Patients with Multiple Sclerosis

    O. Abramsky;R. P. Lisak;D. H. Silberberg;David E Pleasure

  • Enrichment of Schwann cell cultures from neonatal rat sciatic nerve by differential adhesion

    B. Q. Kreider;B. Q. Kreider;A. Messing;A. Messing;H. Doan;H. Doan;S. U. Kim;S. U. Kim

  • Mitogens for glial cells: a comparison of the response of cultured astrocytes, oligodendrocytes and schwann cells

    Rebecca M. Pruss;Perry F. Bartlett;Jelena Gavrilovic;Robert P. Lisak

  • Role of neuropoietic cytokines in development and progression of diabetic polyneuropathy: from glucose metabolism to neurodegeneration

    Dusanka S. Skundric;Robert P. Lisak

  • Antimyelin antibodies in neurologic diseases. Immunofluorescent demonstration.

    Robert P. Lisak;Burton Zwiman;Michael Norman

  • Multiple sclerosis: BAFF and CXCL13 in cerebrospinal fluid.

    Samia Ragheb;Yanfeng Li;Kirk Simon;Stephen VanHaerents

Frequent Co-Authors

Burton Zweiman
Burton Zweiman University of Pennsylvania
David E Pleasure
David E Pleasure University of California, Davis
Peter G. E. Kennedy
Peter G. E. Kennedy University of Glasgow
Timothy A. Pedley
Timothy A. Pedley Columbia University
Amit Bar-Or
Amit Bar-Or University of Pennsylvania
Michael E. Selzer
Michael E. Selzer Temple University
Michael J. Aminoff
Michael J. Aminoff University of California, San Francisco
Richard T. Johnson
Richard T. Johnson Johns Hopkins University School of Medicine
Douglas W. Zochodne
Douglas W. Zochodne University of Alberta
Christopher Kennard
Christopher Kennard University of Oxford

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in Immunology, pursuing related nursing degrees can open diverse career opportunities, especially in specialized healthcare settings. Many professionals leverage cheapest psych np programs online to gain expertise in mental health, which complements immunological knowledge in treating autoimmune or neuroimmune disorders.

Understanding earning potential is crucial when selecting a career path. Looking into how much do dnps make can provide insight into financial expectations for Doctor of Nursing Practice graduates, guiding decisions toward rewarding specialties.

For those already working as family nurse practitioners (FNPs), transitioning to acute care through acnp programs offers specialized skills needed for critical care environments, often intersecting with immunology in treating complex infections or immune-compromised patients.

Additionally, if you seek to fast-track your nursing education, examining the accelerated nurse practitioner program options provides pathways to quickly enter the workforce with advanced qualifications relevant to immunology-related healthcare roles.

Best Scientists Citing Robert P. Lisak

Trending Scientists

Recently Published Articles